Opinion
Video
Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.
- What clinical and patient-specific factors influence your treatment selection between BTK inhibitors for treatment-naive patients with CLL and MCL?
- How do your factors align with or differ from your patients’ preferences and values?
